Dr. Robert A. Sisk, MD
Ophthalmology (Ophthalmology Physician)
- Medicare participating
At a glance
- Medical school
- University of Kentucky College of Medicine (2003)
- Years since graduation
- 23
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 593
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2003Medical school: University of Kentucky College of Medicine
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Ophthalmology Physician primary
OH license 35.093058 · FL license ME98454 · KY license 42600
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Cincinnati Children's Hospital Medical Center Cincinnati, OH
Medical groups
- Children's Hospital Medical Center (711 clinicians)
- Cei Physicians Psc, LLC (158 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 593
- Services billed
- 33,317
- Patients’ average age
- 76
| Service | Times | Patients |
|---|---|---|
| Injection, faricimab-svoa, 0.1 mg | 32,100 | 84 |
| Injection, verteporfin, 0.1 mg | 1,790 | 12 |
| Imaging of retina | 1,607 | 590 |
| Injection, aflibercept, 1 mg | 1,414 | 145 |
| Injection of drug into eye | 1,284 | 280 |
| Unclassified biologics | 667 | 122 |
| Injection, brolucizumab-dbll, 1 mg | 432 | 14 |
| Established patient office or other outpatient visit, 30-39 minutes | 388 | 290 |
| Established patient office or other outpatient visit, 20-29 minutes | 329 | 229 |
| Established patient complete exam of visual system | 104 | 103 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Prednisolone Acetate Other prescribers in Cincinnati, OH | 225 |
| Polymyxin B Sul-Trimethoprim (polymyxin b sulf/trimethoprim) | 88 |
| Dorzolamide-Timolol (dorzolamide hcl/timolol maleat) Other prescribers in Cincinnati, OH | 37 |
| Dorzolamide Hcl Other prescribers in Cincinnati, OH | 36 |
| Moxifloxacin (moxifloxacin hcl) Other prescribers in Cincinnati, OH | 24 |
| Timolol Maleate Other prescribers in Cincinnati, OH | 20 |
| Ofloxacin Other prescribers in Cincinnati, OH | 16 |
| Atropine Sulfate | 15 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 10 companies reported 49 payments worth $1,421 in total to this clinician.
| Regeneron Healthcare Solutions, Inc. | $520 |
|---|---|
| Genentech USA, Inc. | $224 |
| Regeneron Pharmaceuticals, Inc. | $138 |
| Ani Pharmaceuticals, Inc. | $118 |
| Samsara Vision | $115 |
| Astellas Pharma US Inc | $96.12 |
| Apellis Pharmaceuticals, Inc. | $87.24 |
| AbbVie Inc. | $75.47 |
| Food and Beverage | $1,421 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 2 companies. The companies reported $24,630 in research payments for these studies, mostly to the institutions running them.
- Long-term Follow-Up Study of RGX-314 and Fellow Eye Substudy
AbbVie Inc. - Long-term Follow-Up Study of RGX-314 and Fellow Eye Substudy (RGX-314 SRLTFU)
AbbVie Inc. - A Patient Registry Study for Patients Treated With Voretigene Neparvovec in US
Spark Therapeutics, Inc. · Completed · NCT03597399
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.